Emmaus Life Sciences, Inc. today announced that it has received marketing authorization from the Puerto Rico Department of Health for Endari® (L-glutamine oral powder).
Read More
Emmaus Life Sciences, Inc., today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2023.
Read More
Emmaus today reported that on August 18, 2023, the Board of Directors, including Yutaka Niihara, M.D., Ph.D, determined that Dr. Niihara would no longer serve as Chief Executive Officer of Emmaus, or as Chairman of the Board.
Read More
Emmaus Life Sciences, Inc. today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2023.
Read More
Emmaus today announced that it has received marketing authorization from the Oman Ministry of Health for the commercial distribution and sale of Endari®
Read More